CNR2
Cannabinoid receptor 2
Also known as: CB2, CNR2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P34972
- Gene
- CNR2
- Ensembl
- ENSG00000188822
- Chromosome
- 1
- Canonical length
- 360 aa
- Protein class
- FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters
OverviewNCBI Gene
The cannabinoid delta-9-tetrahydrocannabinol is the principal psychoactive ingredient of marijuana. The proteins encoded by this gene and the cannabinoid receptor 1 (brain) (CNR1) gene have the characteristics of a guanine nucleotide-binding protein (G-protein)-coupled receptor for cannabinoids. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner. These proteins have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. The cannabinoid receptors are members of family 1 of the G-protein-coupled receptors. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
360 residues, UniProt reviewed canonical sequence.
>P34972|CNR2
1 MEECWVTEIA NGSKDGLDSN PMKDYMILSG PQKTAVAVLC TLLGLLSALE NVAVLYLILS
61 SHQLRRKPSY LFIGSLAGAD FLASVVFACS FVNFHVFHGV DSKAVFLLKI GSVTMTFTAS
121 VGSLLLTAID RYLCLRYPPS YKALLTRGRA LVTLGIMWVL SALVSYLPLM GWTCCPRPCS
181 ELFPLIPNDY LLSWLLFIAF LFSGIIYTYG HVLWKAHQHV ASLSGHQDRQ VPGMARMRLD
241 VRLAKTLGLV LAVLLICWFP VLALMAHSLA TTLSDQVKKA FAFCSMLCLI NSMVNPVIYA
301 LRSGEIRSSA HHCLAHWKKC VRGLGSEAKE EAPRSSVTET EADGKITPWP DSRDLDLSDCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CNR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 8.4 nTPM
Expression across tissuesHPA
Tissue
- spleen: 8.4 nTPM
- tonsil: 7 nTPM
- lymph node: 6.9 nTPM
- small intestine: 3.1 nTPM
- appendix: 2.2 nTPM
- skeletal muscle: 1.5 nTPM
Single-cell type
- b-cells: 161 nCPM
- thymocytes: 93 nCPM
- tuft cells: 23 nCPM
- nk-cells: 22 nCPM
- innate lymphoid cells: 11 nCPM
- megakaryocyte-erythroid progenitors: 10 nCPM
Immune cell
- basophil: 49 nTPM
- eosinophil: 35 nTPM
- memory B-cell: 30 nTPM
- naive B-cell: 28 nTPM
- NK-cell: 19 nTPM
- MAIT T-cell: 3.8 nTPM
Brain region
- cerebellum: 2.3 nTPM
- white matter: 2.3 nTPM
- choroid plexus: 2.1 nTPM
- amygdala: 2 nTPM
- basal ganglia: 2 nTPM
- cerebral cortex: 2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.68
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.68
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- immune response
- inflammatory response
- leukocyte chemotaxis
- negative regulation of action potential
- negative regulation of mast cell activation
- negative regulation of synaptic transmission, GABAergic
- response to amphetamine
- response to lipopolysaccharide
- trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CNR2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CNR2 as an antibody target. Whether an autoantibody or antibody against CNR2 could matter depends on whether native CNR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CNR2 is annotated at the cell surface, where native CNR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CNR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...